Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy
Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6810-6821
DOI: 10.1021/acs.jmedchem.4c00404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.04.2024. Verfasst von Dongping Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Na…. Hauptthemen laut MEDLINE: Iridium, B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, Distinguished Young Scholars of Jiangsu Province.
Abstract (Originalsprache)
Anti-PD-L1 immunotherapy, a new lung cancer treatment, is limited to a few patients due to low PD-L1 expression and tumor immunosuppression. To address these challenges, the upregulation of PD-L1 has the potential to elevate the response rate and efficiency of anti-PD-L1 and alleviate the immunosuppression of the tumor microenvironment. Herein, we developed a novel usnic acid-derived Iridium(III) complex, Ir-UA, that boosts PD-L1 expression and converts "cold tumors" to "hot". Subsequently, we administered Ir-UA combined with anti-PD-L1 in mice, which effectively inhibited tumor growth and promoted CD4+ and CD8+ T cell infiltration. To our knowledge, Ir-UA is the first iridium-based complex to stimulate the expression of PD-L1 by explicitly regulating its transcription factors, which not only provides a promising platform for immune checkpoint blockade but, more importantly, provides an effective treatment strategy for patients with low PD-L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China.
- Department of Rheumatology and Immunology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China.
ORCID-Profile: Yuncong Chen, Zhi Su
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Distinguished Young Scholars of Jiangsu Province
- Jiangsu Excellent Postdoctoral Program
- Natural Science Foundation of the Higher Education Institutions of Jiangsu Province
Zitieren
APA
Deng, D., Wang, M., Su, Y., Fang, H., Chen, Y., & Su, Z. (2024). Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy. Journal of Medicinal Chemistry, 67(8), 6810-6821. https://doi.org/10.1021/acs.jmedchem.4c00404
Vancouver
Deng D, Wang M, Su Y, Fang H, Chen Y, Su Z. Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy. Journal of Medicinal Chemistry. 2024;67(8):6810-6821. doi:10.1021/acs.jmedchem.4c00404
BibTeX
@article{Deng2024,
author = {Deng, Dongping and Wang, Mengmeng and Su, Yan and Fang, Hongbao and Chen, Yuncong and Su, Zhi},
title = {Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {8},
pages = {6810--6821},
doi = {10.1021/acs.jmedchem.4c00404}
}
EUVIMED